Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Intensive Care
Published in: Annals of Intensive Care 1/2015

Open Access 01-12-2015 | Review

Mechanisms of antimicrobial resistance in Gram-negative bacilli

Authors: Étienne Ruppé, Paul-Louis Woerther, François Barbier

Published in: Annals of Intensive Care | Issue 1/2015

Login to get access

Abstract

The burden of multidrug resistance in Gram-negative bacilli (GNB) now represents a daily issue for the management of antimicrobial therapy in intensive care unit (ICU) patients. In Enterobacteriaceae, the dramatic increase in the rates of resistance to third-generation cephalosporins mainly results from the spread of plasmid-borne extended-spectrum beta-lactamase (ESBL), especially those belonging to the CTX-M family. The efficacy of beta-lactam/beta-lactamase inhibitor associations for severe infections due to ESBL-producing Enterobacteriaceae has not been adequately evaluated in critically ill patients, and carbapenems still stands as the first-line choice in this situation. However, carbapenemase-producing strains have emerged worldwide over the past decade. VIM- and NDM-type metallo-beta-lactamases, OXA-48 and KPC appear as the most successful enzymes and may threaten the efficacy of carbapenems in the near future. ESBL- and carbapenemase-encoding plasmids frequently bear resistance determinants for other antimicrobial classes, including aminoglycosides (aminoglycoside-modifying enzymes or 16S rRNA methylases) and fluoroquinolones (Qnr, AAC(6′)-Ib-cr or efflux pumps), a key feature that fosters the spread of multidrug resistance in Enterobacteriaceae. In non-fermenting GNB such as Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia, multidrug resistance may emerge following the sole occurrence of sequential chromosomal mutations, which may lead to the overproduction of intrinsic beta-lactamases, hyper-expression of efflux pumps, target modifications and permeability alterations. P. aeruginosa and A. baumannii also have the ability to acquire mobile genetic elements encoding resistance determinants, including carbapenemases. Available options for the treatment of ICU-acquired infections due to carbapenem-resistant GNB are currently scarce, and recent reports emphasizing the spread of colistin resistance in environments with high volume of polymyxins use elicit major concern.
Appendix
Available only for authorised users
Literature
1.
Barbier F, Andremont A, Wolff M, Bouadma L (2013) Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and managment. Curr Opin Pulm Med 19(3):216–228PubMed
2.
3.
Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA et al (2012) International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004–2009. Am J Infect Control 40(5):396–407PubMed
4.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228PubMed
5.
6.
Jones RN (2010) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(Suppl 1):S81–S87PubMed
7.
Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. Int J Antimicrob Agents 43(4):328–334PubMed
8.
Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H et al (2011) High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 184(12):1409–1417PubMed
9.
Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78(4):443–448PubMed
10.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A et al (2013) Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188(8):985–995PubMed
11.
Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P et al (2013) Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: an European perspective. Thorax 68:997–999PubMed
12.
Razazi K, Derde LP, Verachten M, Legrand P, Lesprit P, Brun-Buisson C (2012) Clinical impact and risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria in the intensive care unit. Intensive Care Med 38(11):1769–1778PubMed
13.
Hsueh P-R, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y et al (2010) Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 36:408–414PubMed
14.
Torres A, Cilloniz C, Ferrer M, Gabarrus A, Polverino E, Villegas S et al (2015) Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J 45(5):1353–1363PubMed
15.
16.
Alekshun MN, Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell 128(6):1037–1050PubMed
17.
Luyt CE, Brechot N, Trouillet JL, Chastre J (2014) Antibiotic stewardship in the intensive care unit. Crit Care 18(5):480PubMedCentralPubMed
18.
Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F et al (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41(5):776–795PubMed
19.
Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P (2010) Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 14(3):R113PubMedCentralPubMed
20.
Ambler RP (1980) The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 289(1036):321–331PubMed
21.
22.
Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, MacGowan AP et al (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19(2):141–160PubMed
23.
Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL (2004) Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect 10(1):84–85PubMed
24.
Harris PN, Ferguson JK (2012) Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents 40(4):297–305PubMed
25.
Goldstein FW (2002) Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect 8(12):823–825PubMed
26.
Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E et al (2013) Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488–1495PubMedCentralPubMed
27.
Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD et al (2013) The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 57(6):781–788PubMed
28.
Hilty M, Sendi P, Seiffert SN, Droz S, Perreten V, Hujer AM et al (2013) Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents 41(3):236–249PubMedCentralPubMed
29.
American Thoracic Society (2005) Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388–416
30.
Thiebaut AC, Arlet G, Andremont A, Papy E, Sollet JP, Bernede-Bauduin C et al (2012) Variability of intestinal colonization with third-generation cephalosporin-resistant Enterobacteriaceae and antibiotic use in intensive care units. J Antimicrob Chemother 67(6):1525–1536PubMed
31.
Grohs P, Podglajen I, Guerot E, Bellenfant F, Caumont-Prim A, Kac G et al (2014) Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using daily sampling. Clin Microbiol Infect 20(11):O879–O886PubMed
32.
Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, Woodford N (2013) Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? J Antimicrob Chemother 68(11):2667–2674PubMed
33.
34.
Sirot J, Chanal C, Petit A, Sirot D, Labia R, Gerbaud G (1988) Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Rev Infect Dis 10(4):850–859PubMed
35.
Quale JM, Landman D, Bradford PA, Visalli M, Ravishankar J, Flores C et al (2002) Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 35(7):834–841PubMed
36.
Mammeri H, Laurans G, Eveillard M, Castelain S, Eb F (2001) Coexistence of SHV-4- and TEM-24-producing Enterobacter aerogenes strains before a large outbreak of TEM-24-producing strains in a French hospital. J Clin Microbiol 39(6):2184–2190PubMedCentralPubMed
37.
Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K et al (1999) Multiple antibiotic-resistant Klebsiella pneumoniae and Escherichia coli in nursing homes. JAMA 281(6):517–523PubMed
38.
Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM (1996) Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrob Agents Chemother 40(2):509–513PubMedCentralPubMed
39.
Matsumoto Y, Ikeda F, Kamimura T, Yokota Y, Mine Y (1998) Novel plasmid-mediated beta-lactamase from Escherichia coli that inactivates oxyimino-cephalosporins. Antimicrob Agents Chemother 32:1243–1246
40.
Barthelemy M, Peduzzi J, Bernard H, Tancrède C, Labia R (1992) Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum beta-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytoca. Biochim Biophys Acta 1122(1):15–22PubMed
41.
D’Andrea MM, Arena F, Pallecchi L, Rossolini GM (2013) CTX-M-type beta-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol 303(6–7):305–317PubMed
42.
Woerther PL, Burdet C, Chachaty E, Andremont A (2013) Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 26(4):744–758PubMedCentralPubMed
43.
Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I et al (2006) Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 42(7):925–934PubMed
44.
Ruppé E, Pitsch A, Tubach F, de Lastours V, Chau F, Pasquet B et al (2012) Clinical predictive values of extended-spectrum beta-lactamase carriage in patients admitted to medical wards. Eur J Clin Microbiol Infect Dis 31(3):319–325PubMed
45.
Kantele A, Laaveri T, Mero S, Vilkman K, Pakkanen SH, Ollgren J et al (2015) Antimicrobials increase travelers’ risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae. Clin Infect Dis 60(6):837–846PubMedCentralPubMed
46.
Ruppé E, Armand-Lefevre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y et al (2015) High rate of acquisition but short duration of carriage of multidrug-resistant Enterobacteriaceae after travel to the tropics. Clin Infect Dis. doi:10.​1093/​cid/​civ333 PubMed
47.
Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe A, Sordillo EM et al (2013) Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 56(5):641–648PubMedCentralPubMed
48.
Derde LP, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJ, Gniadkowski M et al (2014) Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 14(1):31–39PubMedCentralPubMed
49.
Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 57(5):1012–1014PubMed
50.
Soubirou JF, Rossi B, Couffignal C, Ruppe E, Chau F, Massias L et al (2015) Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. J Antimicrob Chemother 70(5):1466–1472PubMed
51.
Lepeule R, Ruppe E, Le P, Massias L, Chau F, Nucci A et al (2012) Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum beta-lactamase. Antimicrob Agents Chemother 56(3):1376–1381PubMedCentralPubMed
52.
Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B et al (2011) Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66(11):2628–2631PubMed
53.
European Committe on Antimicrobial Susceptibility Testing—Comité de l’antibiogramme de la Société Française de Microbiologie (2015) Guidelines 2015. http://​www.​eucast.​org. Accessed 3 Mar 2015
54.
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME (2012) Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67(12):2793–2803PubMed
55.
Retamar P, Lopez-Cerero L, Muniain MA, Pascual A, Rodriguez-Bano J (2013) Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 57(7):3402–3404PubMedCentralPubMed
56.
Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A (2012) beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54(2):167–174PubMed
57.
Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ et al (2015) Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. doi:10.​1093/​cid/​civ003
58.
Lopez-Cerero L, Picon E, Morillo C, Hernandez JR, Docobo F, Pachon J et al (2010) Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 16(2):132–136PubMed
59.
Harris PN, Tambyah PA, Paterson DL (2015) Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 15(4):475–485PubMed
60.
Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G et al (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58(8):1072–1083PubMed
61.
De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G et al (2014) Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40(3):380–387PubMed
62.
De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M et al (2014) Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med 40(9):1340–1351PubMed
63.
Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC (2013) Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 56(4):488–495PubMed
64.
Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M et al (2006) High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 12(1):56–62PubMed
65.
Pascual V, Ortiz G, Simo M, Alonso N, Garcia MC, Xercavins M et al (2015) Epidemiology and risk factors for infections due to AmpC beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 70(3):899–904PubMed
66.
Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M et al (2005) Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165(12):1430–1435PubMed
67.
Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T et al (2010) An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 50(3):364–373PubMed
68.
Walsh TR, Weeks J, Livermore DM, Toleman MA (2011) Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 11(5):355–362PubMed
69.
Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M et al (2012) Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18(5):413–431PubMed
70.
71.
Nordmann P, Naas T, Poirel L (2011) Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17(10):1791–1798PubMedCentralPubMed
72.
Ruppé E, Armand-Lefevre L, Estellat C, El-Mniai A, Boussadia Y, Consigny PH et al (2014) Acquisition of carbapenemase-producing Enterobacteriaceae by healthy travellers to India, France, February 2012 to March 2013. Euro Surveill 19(14)
73.
Birgand G, Armand-Lefevre L, Lepainteur M, Lolom I, Neulier C, Reibel F et al (2014) Introduction of highly resistant bacteria into a hospital via patients repatriated or recently hospitalized in a foreign country. Clin Microbiol Infect 20(11):O887–O890PubMed
74.
Barbier F, Ruppé E, Giakkoupi P, Wildenberg L, Lucet J-C, Vatopoulos A et al (2010) Genesis of a KPC-producing Klebsiella pneumoniae after in vivo transfer from an imported Greek strain. Euro Surveill 15(1):19457PubMed
75.
Institut National de Veille Sanitaire (2013) Episodes impliquant des entérobactéries productrices de carbapénèmases en France: situation épidémiologique du 1er avril 2013. http://​www.​invs.​sante.​fr. Accessed 29 Dec 2014
76.
Poirel L, Potron A, Nordmann P (2012) OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597–1606PubMed
77.
Skurnik D, Nucci A, Ruimy R, Lasocki S, Muller-Serieys C, Montravers P et al (2010) Emergence of carbapenem-resistant Hafnia: the fall of the last soldier. Clin Infect Dis 50(10):1429–1431PubMed
78.
Findlay J, Hamouda A, Dancer SJ, Amyes SG (2012) Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy. Clin Microbiol Infect 18(2):140–146PubMed
79.
Goessens WH, van der Bij AK, van Boxtel R, Pitout JD, van Ulsen P, Melles DC et al (2013) Antibiotic trapping by plasmid-encoded CMY-2 beta-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli. Antimicrob Agents Chemother 57(8):3941–3949PubMedCentralPubMed
80.
Billard-Pomares T, Tenaillon O, Le Nagard H, Rouy Z, Cruveiller S, Medigue C et al (2011) Complete nucleotide sequence of plasmid pTN48, encoding the CTX-M-14 extended-spectrum beta-lactamase from an Escherichia coli O102-ST405 strain. Antimicrob Agents Chemother 55(3):1270–1273PubMedCentralPubMed
81.
Lowe CF, McGeer A, Muller MP, Katz K (2012) Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto. Canada. Antimicrob Agents Chemother 56(7):3977–3980PubMed
82.
83.
Galimand M, Courvalin P, Lambert T (2003) Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob Agents Chemother 47(8):2565–2571PubMedCentralPubMed
84.
Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Nishino Y et al (1997) Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae. J Antimicrob Chemother 40(4):543–549PubMed
85.
Jacoby GA (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41(Suppl 2):S120–S126PubMed
86.
Allou N, Cambau E, Massias L, Chau F, Fantin B (2009) Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 53(10):4292–4297PubMedCentralPubMed
87.
Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A (2009) Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22(4):664–689PubMedCentralPubMed
88.
Périchon B, Courvalin P, Galimand M (2007) Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother 51(7):2464–2469PubMedCentralPubMed
89.
Filippa N, Carricajo A, Grattard F, Fascia P, El Sayed F, Defilippis JP et al (2013) Outbreak of multidrug-resistant Klebsiella pneumoniae carrying qnrB1 and blaCTX-M15 in a French intensive care unit. Ann Intensive Care 3(1):18PubMedCentralPubMed
90.
Olaitan AO, Morand S, Rolain JM (2014) Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 5:643PubMedCentralPubMed
91.
Zagorianou A, Sianou E, Iosifidis E, Dimou V, Protonotariou E, Miyakis S et al (2012) Microbiological and molecular characteristics of carbapenemase-producing Klebsiella pneumoniae endemic in a tertiary Greek hospital during 2004-2010. Euro Surveill 17(7)
92.
Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A (2005) Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 49(11):4733–4738PubMedCentralPubMed
93.
Lister PD, Gardner VM, Sanders CC (1999) Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 43(4):882–889PubMedCentralPubMed
94.
Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y et al (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13(6):560–578PubMed
95.
Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22(4):582–610PubMedCentralPubMed
96.
Mesaros N, Glupczynski Y, Avrain L, Caceres NE, Tulkens PM, Van Bambeke F (2007) A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 59(3):378–386PubMed
97.
Tsai MH, Wu TL, Su LH, Lo WL, Chen CL, Liang YH et al (2014) Carbapenem-resistant-only Pseudomonas aeruginosa infection in patients formerly infected by carbapenem-susceptible strains. Int J Antimicrob Agents 44(6):541–545PubMed
98.
Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF (2010) Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 10:45PubMedCentralPubMed
99.
Koutsogiannou M, Drougka E, Liakopoulos A, Jelastopulu E, Petinaki E, Anastassiou ED et al (2013) Spread of multidrug-resistant Pseudomonas aeruginosa clones in a university hospital. J Clin Microbiol 51(2):665–668PubMedCentralPubMed
100.
Willmann M, Bezdan D, Zapata L, Susak H, Vogel W, Schroppel K et al (2015) Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study. J Antimicrob Chemother 70(5):1322–1330PubMed
101.
Kos VN, Deraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA et al (2015) The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob Agents Chemother 59(1):427–436PubMedCentralPubMed
102.
103.
Munoz-Price LS, Weinstein RA (2008) Acinetobacter infection. N Engl J Med 358(12):1271–1281PubMed
104.
Kempf M, Rolain JM (2012) Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 39(2):105–114PubMed
105.
Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM et al (2006) The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 258(1):72–77PubMed
106.
Falagas ME, Rafailidis PI (2007) When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Shock 27(6):605–609PubMed
107.
Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK et al (2015) Colistin-resistant Acinetobacter baumannii: beyond carbapenemresistance. Clin Infect Dis 60(9):1295–1303PubMed
108.
Pogue JM, Cohen DA, Marchaim D (2015) Polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin Infect Dis 60(9):1304–1307PubMedCentralPubMed
109.
Cai Y, Chai D, Wang R, Liang B, Bai N (2012) Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67(7):1607–1615PubMed
110.
Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P et al (2013) Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. MBio 4(3):e00013–e00021
111.
Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE et al (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50(9):2946–2950PubMedCentralPubMed
112.
Hawley JS, Murray CK, Jorgensen JH (2008) Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52(1):351–352PubMedCentralPubMed
113.
Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A (2009) Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 65(2):188–191PubMed
114.
Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P et al (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57(3):349–358PubMed
115.
Ritchie DJ, Garavaglia-Wilson A (2014) A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 59(Suppl 6):S374–S380PubMed
116.
De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G et al (2014) High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 18(3):R90PubMedCentralPubMed
117.
Soubirou JF, Gault N, Alfaiate T, Lolom I, Tubach F, Andremont A et al (2014) Ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii. Scand J Infect Dis 46(3):215–220PubMed
118.
119.
Lambert T, Ploy MC, Denis F, Courvalin P (1999) Characterization of the chromosomal aac(6’)-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 43(10):2366–2371PubMedCentralPubMed
120.
Rahmati-Bahram A, Magee JT, Jackson SK (1996) Temperature-dependent aminoglycoside resistance in Stenotrophomonas (Xanthomonas) maltophilia: alterations in protein and lipopolysaccharide with growth temperature. J Antimicrob Chemother 37(4):665–676PubMed
121.
Looney WJ, Narita M, Mühlemann K (2009) Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 9(5):312–323PubMed
122.
Sanchez MB, Martinez JL (2010) SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 54(1):580–581PubMedCentralPubMed
123.
Garcia-Leon G, Ruiz de Alegria Puiq C, Garcia de la Fuente C, Matinez-Martinez L, Martinez JL, Sanchez MB (2015) High-level quinolone resistance is associated with the overexpression of SmeVWX in Stenotrophomonas maltophilia clinical isolates. Clin Microbiol Infect. doi:10.​1016/​j.​cmi.​2015.​01.​007 PubMed
124.
San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L (2004) Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48(1):168–171PubMedCentralPubMed
125.
Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J (2014) Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 58(1):176–182PubMedCentralPubMed
126.
Tekce YT, Erbay A, Cabadak H, Sen S (2012) Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother 24(3):150–154PubMed
127.
Betts JW, Phee LM, Woodford N, Wareham DW (2014) Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 33(9):1565–1572PubMed
128.
Church D, Lloyd T, Peirano G, Pitout J (2013) Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis 45(4):265–270PubMed
129.
Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L (2014) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1:CD003344PubMed
130.
Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1:CD003344PubMed
131.
Pena C, Suarez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V et al (2013) Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post-hoc analysis of a prospective cohort. Clin Infect Dis 57(2):208–216PubMed
132.
Tamma PD, Cosgrove SE, Maragakis LL (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25(3):450–470PubMedCentralPubMed
133.
Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41(2):149–158PubMed
134.
Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, Bou G, Tomas M, Garnacho-Montero J et al (2014) Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 69(11):3119–3126PubMed
135.
Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999) Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43(6):1379–1382PubMedCentralPubMed
136.
Manian FA, Meyer L, Jenne J, Owen A, Taff T (1996) Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol 17(4):222–226PubMed
137.
Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P et al (1994) Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 38(6):1309–1313PubMedCentralPubMed
138.
Choi SH, Lee JE, Park SJ, Lee SO, Jeong JY, Kim MN et al (2008) Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 52(3):995–1000PubMedCentralPubMed
139.
Poulikakos P, Tansarli GS, Falagas ME (2014) Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33(10):1675–1685PubMed
140.
Latibeaudiere R, Rosa R, Laowansiri P, Arheart K, Namias N, Munoz-Price LS (2015) Surveillance cultures growing carbapenem-Resistant Acinetobacter baumannii predict the development of clinical infections: a retrospective cohort study. Clin Infect Dis 60(3):415–422PubMed
141.
Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A et al (2012) Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55(7):905–914PubMedCentralPubMed
142.
Ruppé E, Lixandru B, Cojocaru R, Buke C, Paramythiotou E, Angebault C et al (2013) Relative fecal abundance of extended-spectrum-beta-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother 57(9):4512–4517PubMedCentralPubMed
143.
Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM et al (2000) Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 343(26):1925–1932PubMedCentralPubMed
144.
Ruppé E, Andremont A (2013) Causes, consequences, and perspectives in the variations of intestinal density of colonization of multidrug-resistant enterobacteria. Front Microbiol 4:129PubMedCentralPubMed
145.
Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M et al (2005) First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 33(2):283–289PubMed
146.
Grohs P, Kerneis S, Sabatier B, Lavollay M, Carbonnelle E, Rostane H et al (2014) Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother 69(3):786–789PubMed
147.
Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I, Poulakou G et al (2011) Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 17(11):E9–E11PubMed
148.
Weiss E, Zahar JR, Lesprit P, Ruppé E, Leone M, Chastre J et al (2015) Elaboration of a consensual definition of de-escalation allowing a ranking of beta-lactams. Clin Microbiol Infect. doi:10.​1016/​j.​cmi.​2015.​03.​013
149.
Le Dorze M, Gault N, Foucrier A, Ruppé E, Mourvillier B, Woerther PL et al (2014) Perfomance and impact of a rapid method combining mass spectrometry and direct antimicrobial susceptibility testing on treatment adequacy of patients with ventilator-associated pneumonia. Clin Microbiol Infect. doi:10.​1016/​j.​cmi.​2014.​12.​007 PubMed
150.
Morosini MI, Garcia-Castillo M, Tato M, Gijon D, Valverde A, Ruiz-Garbajosa P et al (2014) Rapid detection of beta-lactamase-hydrolyzing extended-spectrum cephalosporins in Enterobacteriaceae by use of the new chromogenic Betalacta-test. J Clin Microbiol 52(5):1741–1744PubMedCentralPubMed
151.
Jamal W (2014) Al Roomi E, Abdulaziz LR, Rotimi VO. Evaluation of Curetis Unyvero, a multiplex PCR-based testing system, for rapid detection of bacteria and antibiotic resistance and impact of the assay on management of severe nosocomial pneumonia. J Clin Microbiol 52(7):2487–2492PubMedCentralPubMed
152.
de Smet AM, Kluytmans JA, Blok HE, Mascini EM, Benus RF, Bernards AT et al (2011) Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 11(5):372–380PubMed
153.
de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS et al (2009) Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360(1):20–31PubMed
154.
Roquilly A, Marret E, Abraham E, Asehnoune K (2015) Pneumonia prevention to decrease mortality in intensive care unit: a systematic review and meta-analysis. Clin Infect Dis 60(1):64–75PubMed
155.
Daneman N, Sarwar S, Fowler RA, Cuthbertson BH (2013) Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13(4):328–341PubMed
156.
Oostdijk EA, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EH et al (2014) Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 312(14):1429–1437PubMed
157.
Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-Grauls CM (2013) Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 57(7):3224–3229PubMedCentralPubMed
158.
Lubbert C, Faucheux S, Becker-Rux D, Laudi S, Durrbeck A, Busch T et al (2013) Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents 42(6):565–570PubMed
159.
Brink AJ, Coetzee J, Corcoran C, Clay CG, Hari-Makkan D, Jacobson RK et al (2013) Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol 51(1):369–372PubMedCentralPubMed
160.
Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y et al (2012) A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 33(1):14–19PubMed
161.
Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K et al (2013) Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial. Am J Infect Control 41(12):1167–1172PubMed
162.
Bassetti M, Righi E (2014) SDD and colistin resistance: end of a dream? Intensive Care Med 40(7):1066–1067PubMed
163.
Kollef MH, Micek ST (2014) Rational use of antibiotics in the ICU: balancing stewardship and clinical outcomes. JAMA 312(14):1403–1404PubMed
164.
Drawz SM, Papp-Wallance KM, Bonomo RA (2014) New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58(4):1835–1846PubMedCentralPubMed
165.
Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR et al (2013) Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs 73(2):159–177PubMed
166.
Testa R, Canton R, Giani T, Morosini MI, Nichols WW, Seifert H et al (2015) In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents. doi:10.​1016/​j.​ijantimicag.​2014.​12.​033 PubMed
167.
Li H, Estabrook M, Jacoby GA, Nichols WW, Testa R, Bush K (2015) In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59(3):1789–1793PubMed
168.
Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN (2014) Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 58(3):1684–1692PubMedCentralPubMed
169.
Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J et al (2015) Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. doi:10.​1093/​cid/​civ097 PubMedCentralPubMed
170.
Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ (2013) Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56(2):272–282PubMed
171.
Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S et al (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54(12):1720–1726PubMedCentralPubMed
172.
Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A et al (2012) Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117(6):1335–1347PubMed
Metadata
Title
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Authors
Étienne Ruppé
Paul-Louis Woerther
François Barbier
Publication date
01-12-2015
Publisher
Springer Paris
Published in
Annals of Intensive Care / Issue 1/2015
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-015-0061-0

Other articles of this Issue 1/2015

Annals of Intensive Care 1/2015 Go to the issue

Review

Non-invasive monitoring of oxygen delivery in acutely ill patients: new frontiers

Erratum

Erratum to: Experts’ recommendations for the management of adult patients with cardiogenic shock

Review

Extravascular lung water in critical care: recent advances and clinical applications

Research

Right over left ventricular end-diastolic area relevance to predict hemodynamic intolerance of high-frequency oscillatory ventilation in patients with severe ARDS

Research

Influence of ICU-bed availability on ICU admission decisions

Research

Long-term survival and quality of life after intensive care for patients 80 years of age or older